Abstract 471P
Background
Despite being a rare disease entity, Thymoma and Thymic carcinomas represent the most common cause of anterior mediastinal mass. Clinical course is widely varied from an indolent course to florid metastatic disease with paraneoplastic manifestation. Treatment guidelines are based on small phase 2 studies. Data of chemotherapy in advanced thymoma is limited.
Methods
It is a retrospective study of advanced thymic epithelial tumors treated with chemotherapy over a period of 7 years (2011 -2017). All patients with unresectable /metastatic thymic tumours and who have received chemotherapy as were included in the study. Independent review of radiology images and histopathology slides were performed.
Results
There were 55 cases registered with thymic malignancy and 32 cases were analyzed for present study. Among them 27 cases were thymoma, 3 were thymic carcinoma and 2 were thymic NET. The median age was 39 years (22 65 years). Male: female ratio was 3: 1. The median duration of symptoms was 5.9 months (0-36 months). Twelve cases (38%) had features of superior vena cava obstruction at presentation. The mean size of mediastinal mass was 8.9 + 3.26 (range 2-15 cm). More than half of the cases (56%) showed calcification. Mediastinal lymph nodes were seen in 14 patients (46%). There was pleural involvement in 14 patients (73%) and pericardial involvement in 13 cases (43%). Pleural effusion was seen in 17(53%). Only 5 cases had stage III, 18 had stage Iva and 9 had stage IVb disease. The most common histological subtype as per WHO classification was B1 in 11 patients (34%) followed by B3 in 9 patients (28%) in our cohort. Out of 32 cases 3 have had upfront R2 resection. Post chemotherapy, one case attained CR, 10 had PR, 13 had SD and 3 had PD. 6 cases underwent surgery post induction therapy. 3 had R1 resection and 3 had R2 resection. Cisplatin, doxorubicin and cyclophosphamide (CAP) remains first choice for chemotherapy in 81% patients followed by paclitaxel-carboplatin in 12.5%. Radiation therapy was given to 13 patients. After a median follow up of 24.86 months, median PFS is 16.1 months and median OS was not reached.
Conclusions
Thymic malignancies are a heterogeneous group of disorders. Multi-modality treatment including chemotherapy is an effective and feasible treatment for advanced thymoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
All authors are equally responsible. Institute ethics committee has given the clearance.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract
YO19 - A case of CLL/SLL with transdifferentiation to dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm:The missing link?
Presenter: Yanping Chen
Session: Poster display session
Resources:
Abstract